Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
OXILAN-350 is an injectable diagnostic agent marketed by Guerbet, approved in 1995 as an NDA. The specific mechanism of action and therapeutic indications are not publicly disclosed in available data, though the injectable route suggests use in imaging or diagnostic procedures.
As a mature product approaching loss of exclusivity with moderate competitive pressure (30%), the brand team is likely focused on lifecycle extension and managing decline rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
OXILAN-350 offers limited career growth opportunity given zero linked job openings and approaching LOE status. Roles available focus on lifecycle management, pricing defense, and operational efficiency rather than launch or growth strategy.
Worked on OXILAN-350 at Guerbet? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.